Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma

Cancer

Volumn 101, Issue 6, 2004, Pages 1455-1462

  Leitao, Mario M ^a   Soslow, Robert A ^a   Nonaka, Daisuke ^a   Olshen, Adam B ^a   Aghajanian, Carol ^a   Sabbatini, Paul ^a   Dupont, Jakob ^a   Hensley, Martee ^a   Sonoda, Yukio ^a   Barakat, Richard R ^a   Anderson, Sibyl ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Recurrence; Steroid receptors; Survival; Tissue microarray; Uterine leiomyomata (LMA); Uterine leiomyosarcoma (LMS)

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; TREATMENT OUTCOME; UTERUS MYOMA;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; MIDDLE AGED; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; UTERINE NEOPLASMS;

EID: 4444252760     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20521     Document Type: Article

References (26)

1. Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst. 1986;76:399-402.
2. Zaloudek C, Norris HJ. Mesenchymal tumors of the uterus. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. New York: Springer-Verlag, 1994;487-528.
3. Leitao M Jr., Sonoda Y, Brennan MF, Barakat R, Chi DS. Incidence of lymph node and ovarian metastases in uterine leiomyosarcoma. Gynecol Oncol. 2003;91:209-212.
4. Berchuck A, Rubin SC, Hoskins WJ, et al. Treatment of uterine leiomyosarcoma. Obstet Gynecol. 1988;71:845-850.
5. Entman SE. Uterine leiomyoma and adenomyosis. In: Jones HW III, Wentz AC, Burnett LS, editors. Novak's textbook of gynecology. Baltimore: Williams & Wilkins, 1988;443.
6. Fuchs-Young R, Howe S, Hale L, Miles R, Walker C. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Mol Carcinog. 1996;17:151-159.
7. Palomba S, Russo T, Orio F Jr., et al. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, single-blind, placebo-controlled clinical trial. Hum Reprod. 2002; 17:3213-3219.
8. Zhai Y, Kobayashi Y, Mori A, et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Palhol. 1999;18:20-28.
9. Soper JT, McCarty KS Jr., Hinshaw W, Creasman WT, McCarty KS Sr., Clarke-Pearson DL. Cytoplasmic estrogen and progesterone receptor content of uterine sarcomas. Am J Obstet Gynecol. 1984;150:342-348.
10. Sutton GP, Stehman FB, Michael H, Young PCM, Ehrlich CE. Estrogen and progesterone receptors in uterine sarcomas. Obstet Gynecol. 1986;68:709-714.
11. Wade K, Quinn MA, Hammond I, Williams K, Cauchi M. Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol Oncol. 1990;39:364-367.
12. Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol. 2001;32:984-987.
13. Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathologic parameters. Anticancer Res. 2003;23:729-732.
14. Uchida T, Nakakawaji K, Sakamoto J, et al. The effectiveness of medroxyprogesterone in the treatment of multiple metastasizing leiomyosarcomas: report of a case. Surg Today. 1996;26:138-141.
15. Silva EG, Tornos CS, Follen-Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol. 1994;13:248-258.
16. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847.
17. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms: a clinicopathologic study of 213 cases. Am J Surg Pathol. 1994;18:535-558.
18. Leitao MM, Brennan MF, Hensley M, et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol. 2002;87:287-294.
19. Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol. 1985;3:1240-1245.
20. Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage 1 and II uterine sarcoma. Int J Radiat Oncol Biol Phys. 1986;12:2127-2130.
21. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824-2831.
22. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol. 1994;83:414-418.
23. aakamizawa S, Minakami H, Usui R, et al. Risk of complications and uterine malignancies in women undergoing hysterectomy for presumed benign leiomyomas. Gynecol Obstet Invest. 1999;48:193-196.
24. Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endomettial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:4-9.
25. Fiorica IV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:10-14.
26. Tseng L, Tseng JK, Mann WJ, et al. Endocrine aspects of human uterine sarcoma: a preliminary study. Am J Obstet Gynecol. 1986;155:95-101.